Holen Sie sich die Stockscreener-App
0.0739
37.11%
-0.0436
Bioxcel Therapeutics Inc Aktie (BTAI) Neueste Nachrichten
BioXcel Therapeutics (BTAIQ) Beta - Zacks Investment Research
BioXcel Therapeutics (BTAIQ) Eps Diluted (TTM) - Zacks Investment Research
All News for BTAIQ : BioXcel Therapeutics - Zacks Investment Research
BTAIQ: BioXcel TherapeuticsPrice & EPS Surprise - Zacks Investment Research
BioXcel Therapeutics, Inc. Revenue Breakdown – OTC:BTAIQ - TradingView
BTAIQ Stock Price Chart - eToro
Meet The Attorneys Guiding BioXcel Therapeutics' Ch.11 - Law360
Biotech filed for bankruptcy 11 weeks before its big FDA decision - thestreet.com
BioXcel Therapeutics, Inc.(OTCPK: BTAI.Q) dropped from NASDAQ Composite Index - marketscreener.com
Bioxcel Therapeutics Stock Price Forecast. Should You Buy BTAI? - StockInvest.us
symbol__ Stock Quote Price and Forecast - CNN
Teva (TEVA) Backed a Bid of Up to $125M in Cash Plus Assumed Liabilities for BioXcel’s Assets. Is Bankruptcy-Sale Risk Worth the At-Home Opportunity? - finance.yahoo.com
Dow Falls Over 100 Points; US Economy Adds 162,000 Jobs In August - Benzinga
BioXcel Therapeutics, Inc. Share Price Live Today – NASDAQ:BTAI Stock Price, Chart, News, History - Upstox
BioXcel (BTAI) Stock News & Analysis - TechStock²
Case Summary: BioXcel Therapeutics Chapter 11 - Bondoro
$BioXcel Therapeutics (BTAI.US)$ only know .135-.115 it be like that - Moomoo
$BioXcel Therapeutics (BTAI.US)$ .1055 looking secured. investor terms liquidity zone looks full.🤔🧐 - Moomoo
BioXcel Therapeutics Company Profile & Introduction - Moomoo
BioXcel Therapeutics, Inc.(NasdaqCM: BTAI) dropped from S&P TMI Index - marketscreener.com
BioXcel Therapeutics Inc (NASDAQ: BTAI) Share Price, BTAI Stock News, BTAI Share Price & Updates - Kalkine
BioXcel Therapeutics, Inc.(NasdaqCM: BTAI) dropped from Russell 3000E Index - marketscreener.com
BioXcel Secures DIP Financing Amid Nasdaq Delisting Move - TipRanks
BioXcel Therapeutics Received Notice of Delisting - TradingView
BioXcel agrees to $77M DIP as Nasdaq delists - Stock Titan
Teva Bids $57.5 Million for BioXcel's Agitation Drug in Bankruptcy Auction - finance.biggo.com
Teva Seeks to Boost Neuroscience Portfolio With BioXcel Asset Bid - Yahoo Finance
Teva Pharmaceuticals to acquire BioXcel assets for up to $125m - Yahoo Finance
BioXcel Stock Crashes 74.8% as Teva’s $57.5 Million Bid Meets Chapter 11 - TechStock²
BioXcel Therapeutics Files Chapter 11, Lines Up $125M Teva Asset Sale - ElevenFlo
Dow Gains 100 Points; Chicago PMI Falls In August - Sahm
Deal Dispatch: Carets Corp Explores Strategic Alternatives, nVent Electric Buys Maverick Power for $1.75 - Benzinga
M&A Roundup: DualityBio & Genentech Enter Partnership to Develop Next Generation ADC’s, Teva Bids to Acquire Igalmi from BioXcel - Pharmaceutical Executive
Teva Sinks on Bid to Buy BioXcel - Baystreet.ca
BioXcel Therapeutics Files Chapter 11, Agrees to Asset Sale With Teva - citybiz
Teva bids $57.5M for BioXcel’s agitation treatment asset By Investing.com - Investing.com UK
Teva Pharmaceutical Industries to Bid on BioXcel Therapeutics’ BXCL501 Dexmedetomidine Sublingual Film in Court-Supervised Sale Process - Quiver Quantitative
Teva Pharmaceutical Industries Ltd - Via Ritzau
BioXcel Therapeutics Picks Teva as Stalking Horse in $57.5M Asset Sale, Up to $87.5M in Milestones - TradingView
BTAI Looks 33.2% Overvalued on GF Value™ Amid Bankruptcy Filing - GuruFocus
L'azienda biofarmaceutica BioXcel Therapeutics presenta istanza di fallimento negli Stati Uniti - TradingView
Motion for Joint Administration Filed by BioXcel Therapeutics, Inc. - marketscreener.com
BioXcel Therapeutics Amends Credit Agreement Amid Liquidity Strain - The Globe and Mail
BioXcel Therapeutics Adds $1.25 Million Oaktree Term Loans, Wins Liquidity Covenant Relief - TradingView
Bioxcel Therapeutics Enters Fourteenth Amendment To Credit Agreement On August 24, 2026 - TradingView
ARMISTICE CAPITAL, LLC Reduces BioXcel Therapeutics Inc (BTAI) S - GuruFocus
BioXcel Therapeutics Faces August 21 Oaktree Transaction Deadline As $13.8 Million Cash Funds Operations Only Through August - Pulse 2.0
BioXcel (BTAI) Session Check: Ends Down by 11.01% at $0.79; Chart Reference: the $0.75 to $0.83 Range Remains in Focus on the DayCatalyst Driven Stocks - vinanet.vn
BioXcel Shareholder Notice - TMX Newsfile
BioXcel Therapeutics earnings missed by $0.07, revenue fell short of estimates - Investing.com
BioXcel Therapeutics (BTAI) director receives option grant for 17,000 shares - Stock Titan
BioXcel Therapeutics (BTAI) files Form 3 for new director Susan E. Atkins - Stock Titan
Armistice Capital (BTAI) discloses 4.99% BioXcel Therapeutics stake via managed fund - Stock Titan
BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
BioXcel Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
BioXcel Therapeutics (BTAI) flags going concern risk with high debt and cash strain - Stock Titan
BioXcel Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
BTAI Q1 2026 Earnings: Narrower Loss Beats Estimates, Shares Rally 7.08%Guidance Upgrade Report - vinanet.vn
BioXcel Deadline Alert - TMX Newsfile
BioXcel Therapeutics Wins Liquidity Relief as Oaktree Cuts Minimum Cash Covenant to $3 Million - Minichart
BioXcel amends Oaktree-led credit agreement, cuts minimum liquidity covenant to $3 million - Bitget
BioXcel Therapeutics Amends Oaktree Credit Pact, Extends Deal Deadline and Lowers Liquidity Floor - TradingView
BioXcel Therapeutics (BTAI) cuts liquidity covenant, faces August 2026 refinancing deadline - Stock Titan
BioXcel Therapeutics, Inc. Enters Into Twelfth Amendment To Credit Agreement And Guaranty And First Amendment To Security Agreement - marketscreener.com
BTAI News | BIOXCEL THERAPEUTICS INC (NASDAQ:BTAI) - ChartMill
0.35%
1.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):